Mathé G, Bayssas M, Gouveia J, Dantchev D, Ribaud P, Machover D, Misset J L, Schwarzenberg L, Jasmin C, Hayat M
Cancer Chemother Pharmacol. 1978;1(4):259-62. doi: 10.1007/BF00257160.
A phase II trial of which preliminary results are available for 22 patients indicates that aclacinomycin applied in a continuous modality induced complete and partial remission in four of nine patients with acute lymphoid leukaemia that was resistant to all previously available drugs, and in four of eight patients with stage V lymphosarcoma (leukaemic). Bone-marrow toxicity was the major side-effect. Only one patient of 20 suffered from cardiac toxicity; no one had alopoecia. This very low incidence of myocardial lesions and the absence of hair loss had been predicted, respectively, by our electron microscope study of the myocardium and the light electron microscope study of the skin of golden hamsters [7], a test that detects frequent severe myocardium and skin toxicities for adriamycin and some anthracyclin analogues such as detorubicin, which was found to be toxic in a high percentage of patients in a clinical trial conducted by the E.O.R.T.C. Clinical Screening Group [8].
一项有22例患者初步结果可用的II期试验表明，以持续方式应用阿克拉霉素可使9例对所有先前可用药物均耐药的急性淋巴细胞白血病患者中的4例以及8例V期淋巴肉瘤（白血病型）患者中的4例实现完全缓解和部分缓解。骨髓毒性是主要副作用。20例患者中仅有1例出现心脏毒性；无人发生脱发。我们分别通过对金黄地鼠心肌的电子显微镜研究以及对其皮肤的光电子显微镜研究预测到心肌病变发生率极低且无脱发情况[7]，该试验可检测到阿霉素及一些蒽环类类似物（如去甲柔红霉素）频繁引发的严重心肌和皮肤毒性，欧洲癌症治疗研究组织（E.O.R.T.C.）临床筛查小组进行的一项临床试验发现，去甲柔红霉素在高比例患者中具有毒性[8]。
